Latest Pharmaceuticals News

LTR Pharma has successfully completed the extractables study for its intranasal erectile dysfunction spray SPONTAN, confirming safety compliance and initiating the next phase of leachables testing to support FDA approval.

Firebrick Pharma has raised $0.2 million in a placement well below its $1.6 million target, prompting a review of its expansion and product development plans for Nasodine.

Paradigm Biopharmaceuticals has acquired Proteobioactives, securing global rights to an oral combination therapy targeting early-stage osteoarthritis in humans and animals, complementing its injectable PPS phase 3 program.

Hydralyte USA reported its strongest monthly sales in May 2025, alongside continued improvement in EBITDA losses, signaling steady progress toward profitability.

Mayne Pharma shareholders have overwhelmingly approved a scheme for Cosette Pharmaceuticals to acquire the company, setting the stage for a pivotal court hearing later this year.

CLINUVEL’s Phase II pilot study reveals afamelanotide monotherapy does not trigger repigmentation in vitiligo patients, underscoring the necessity of adjunct NB-UVB phototherapy.

Mayne Pharma shareholders have overwhelmingly approved the scheme of arrangement for Cosette Pharmaceuticals to acquire the company at $7.40 per share, despite ongoing legal challenges and regulatory approvals still pending.

Bioxyne Limited, through its subsidiary Breathe Life Sciences, has secured a significant supply agreement to enter Germany’s burgeoning medical cannabis market, promising at least A$5.6 million in revenue for FY2026.

Bioxyne Limited's subsidiary Breathe Life Sciences has achieved key GMP certifications across multiple international markets, paving the way for expanded operations in Europe, the UK, Canada, and Singapore. The company signals strong growth prospects for FY2026, with formal guidance expected in August.

Recce Pharmaceuticals has locked in a non-dilutive A$30 million debt facility with Avenue Capital Group, extending its cash runway to support pivotal Phase 3 trials and commercialisation of its synthetic anti-infective R327G.

Mayne Pharma rejects Cosette Pharmaceuticals’ claims of valid termination of their scheme deal, setting the stage for a September court showdown while urging shareholders to back the scheme in June.

Nyrada’s Phase I clinical trial for its novel drug Xolatryp has cleared safety reviews through four cohorts and will now test higher doses and longer infusions in an expanded trial design.